Skip to main content

Advertisement

SpringerLink
Log in

Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Le Cesne A, Jy B, Judson I et al (2005) Phase II study of ET-743 in advanced soft-tissue sarcomas: an European organisation for the research and treatment of cancer (EORTC) soft tissue and bone group trial. J Clin Oncol 23:576–584. doi:10.1200/JCO.2005.01.180

    Article  PubMed  Google Scholar 

  2. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759. doi:10.1200/JCO.2006.07.3049

    Article  PubMed  Google Scholar 

  3. James K, Eisenhauer E, Christian M et al (1999) Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91:523–528. doi:10.1093/jnci/91.6.523

    Article  CAS  PubMed  Google Scholar 

  4. Grosso F, Jones RL, Demetri GD et al (2007) Efficacy of trabectedin (estenascidin 743) in advanced pretreated myxoid liposarcoma: a retrospective study. Lancet Oncol 8:595–602. doi:10.1016/S1470-2045(07)70175-4

    Article  CAS  PubMed  Google Scholar 

  5. Fayette J, Ray-Coquard I, Alberti L, Ranchère D, Boyle H, Blay JY (2005) ET-743: a novel agent with activity in soft tissue sarcoma. Oncologist 10:827–832. doi:10.1634/theoncologist.10-10-827

    Article  CAS  PubMed  Google Scholar 

  6. Verweij J (2008) Other endpoints in screening studies for soft tissue sarcomas. Oncologist 13(suppl 2):S27–S31. doi:10.1634/theoncologist.13-S2-27

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’Oncologie Médicale, Centre Oscar Lambret, Lille, France

    Antoine Hollebecque, Antoine Adenis & Nicolas Penel

  2. Département d’Imagerie, Centre Oscar Lambret, Lille, France

    Sophie Taieb

  3. PharmaMar, Colmenar Viejo, Madrid, Spain

    Claudia Lebedinsky

  4. Equipe d’Accueil 2694: Santé Publique, Epidémiologie et modélisation des maladies chroniques, Université Lille II, Lille, France

    Nicolas Penel

  5. Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020, Lille, France

    Antoine Hollebecque

Authors
  1. Antoine Hollebecque
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoine Adenis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sophie Taieb
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudia Lebedinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicolas Penel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoine Hollebecque.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hollebecque, A., Adenis, A., Taieb, S. et al. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Invest New Drugs 28, 529–530 (2010). https://doi.org/10.1007/s10637-009-9262-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9262-4

Keywords

Search

Navigation